DODAP
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


DODAP
Description :
DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests) . DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation[1][2][3][4][5].UNSPSC :
12352211Hazard Statement :
H302, H315, H319, H335Target :
LiposomeType :
OligonucleotidesRelated Pathways :
Metabolic Enzyme/ProteaseApplications :
COVID-19-immunoregulationField of Research :
Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/dodap.htmlPurity :
98.0Solubility :
DMSO : 100 mg/mL (ultrasonic) |Ethanol : ≥ 100 mg/mLSmiles :
CCCCCCCC/C=C\CCCCCCCC(OC(CN(C)C)COC(CCCCCCC/C=C\CCCCCCCC)=O)=OMolecular Formula :
C41H77NO4Molecular Weight :
648.05Precautions :
H302, H315, H319, H335References & Citations :
[1]Dabbas S, et al. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium. 2008;15 (4) :189-201.|[2]Hamzah J, et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol. 2009;183 (2) :1091-1098.|[3]Liu Q, et al. Biotinylated cyclen-contained cationic lipids as non-viral gene delivery vectors. Chem Biol Drug Des. 2013;82 (4) :376-383.|[4]Carrasco MJ, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol. 2021 Aug 11;4 (1) :956.|[5]Mendonça LS, et al. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem. 2010 Jan;21 (1) :157-68.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
OligonucleotidesClinical Information :
No Development ReportedCAS Number :
[127512-29-2]

